Busulfan is a common cancer drug that is known to slow down the neoplastic activity of malignant cells. More specifically, it is a generic and non-specific cell type alkylating antineoplastic agent. It has been initially created as a therapeutic drug for chronic myeloid leukemia, and has been reclassified to a generic acting medication for cancer cells.
The drug is described to be able to control the burden of tumor formation and significantly slow down metastasis of the cancer cells to other regions in the body. However, it is not able to fully impede the progress of it, as it is incapable of reversing the overall cellular aberration effects by the cancer cells. Cytogenic abnormalities still continue to progress in this manner, but at a better rate of slowdown than without medication.
Busulfan is given to typical cancer patients who are susceptible for chemotherapy and drug induction therapy. The mechanism of the drug in a cellular level is characterized by the production of Guanine-guanine strands of genetic output as the drug attacks the carbon strand in the mesylate group in a malignant cancer cell. This occurs in large success rates for the target cancer cell and results to an apoptotic state. However, the result may also generally decrease overall strength as massive cellular destruction on the target area is being done as evidenced by destruction of normal cells, especially in bone marrows.
It is also an alternative option for non-operative stem cell transplantation, therefore increasing receptivity for an oncoming transplant of stem cells.
Cancer patients should have proper information regarding the effects of the drug, with the proper supervision and expertise of a qualified physician.
Busulfan is considered as a palliative drug in dosages of 60 micrograms per body weight in kilos, with a maximum of 4 milligrams per day.
For treatment of Polycythemia vera, 4 to 6 milligrams is recommended per day over a course of 4 to 6 weeks.
For essential thrombocythaemia, 2 to 4 milligrams per day is recommended.
Conditioning therapeutic medication plans call for about 3.5 to 4 milligram per body weight in kilos per day, given in four doses, totaling 14 to 16 milligrams per kilo body weight.
Side effects for Busulfan medication may include general toxicity leading to fibrosis in the pulmonary tract, seizures, wasting of the muscles and organs, and cases of liver malfunction and failure. As for the seizures, phenytoin medication may be used to lessen the occurrence.
It is important to let the attending or prescribing physician know the medications being used to determine possible drug-to-drug interactions. This holds most special consideration with antifungal medications such as azole variants. It also is contraindicated with acetaminophens, phenothiazines and other cancer drugs such as cyclosporine.
If contraindications of drugs is suspected or determined, it would be advisable to take medication and cautiously use the product three days after last previous drug is used.
Acetaminophen is prevented to be used alongside Busulfan since it raises blood levels and may increase the risk of complicated hypertension.
Busulfan has the following structural formula:
• Molecular formula of busulfan is C6H14O6S2
• Chemical IUPAC Name is 1,4-bis(methylsulfonyloxy)butane
• Molecular weight is 246.304 g/mol
Brand name(s): Busulfex, Busulphan, Busulphane, Buzulfan, Citosulfan, Leucosulfan, Mablin, Mielevcin, Mielosan, Mielucin, Milecitan, Mileran, Misulban, Mitosan, Mitostan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Sulphabutin
Review published on: 20 June 2009
 Your Busulfan review
Other popular drugs: Levothroid ::
Chlorambucil ::
Gefitinib
|
Home
E-Mail
Site Map
http://www.medical-look.com
FORUM 
Buy Busulfan
